(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of
Continue reading »![](https://mypharmacynews.com/wp-content/uploads/sites/11/2020/07/cfarmafoto1-pembrolizuma.jpg)
mypharmacynews.com
Home »
(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of
Continue reading »At least 25 percent of critically ill patients who receive mechanical ventilation in intensive care units (ICUs) develop muscular weakness
Continue reading »